Hinge Health, Inc. (HNGE)
| Market Cap | 6.80B +85.7% |
| Revenue (ttm) | 646.34M +49.8% |
| Net Income | -511.39M |
| EPS | -7.27 |
| Shares Out | 77.38M |
| PE Ratio | n/a |
| Forward PE | 31.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 501,077 |
| Open | 89.09 |
| Previous Close | 89.92 |
| Day's Range | 87.45 - 90.53 |
| 52-Week Range | 30.08 - 91.07 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 82.07 (-6.6%) |
| Earnings Date | Aug 4, 2026 |
About HNGE
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, C... [Read more]
Financial Performance
In 2025, Hinge Health's revenue was $587.86 million, an increase of 50.58% compared to the previous year's $390.40 million. Losses were -$424.09 million, 3453.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for HNGE stock is "Buy." The 12-month stock price target is $82.07, which is a decrease of -6.60% from the latest price.
News
Hinge Health to announce second quarter 2026 financial results on August 4, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended June 30, 2026, after the U.S. financial markets close on...
Hinge Health price target raised to $90 from $80 at Wells Fargo
Wells Fargo raised the firm’s price target on Hinge Health (HNGE) to $90 from $80 and keeps an Overweight rating on the shares. The firm called the consensus conservative, and…
Omada Health has ‘catch up potential,’ says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach says it is “overlooked” that Omada Health (OMDA) is significantly more profitable at their current revenue than where Hinge Health (HNGE) was at similar revenue...
Hinge Health price target raised to $65 from $55 at Baird
Baird raised the firm’s price target on Hinge Health (HNGE) to $65 from $55 and keeps a Neutral rating on the shares.
Hinge Health price target raised to $80 from $70 at Raymond James
Raymond James raised the firm’s price target on Hinge Health (HNGE) to $80 from $70 and keeps an Outperform rating on the shares following last week’s investor day. The firm…
Hinge Health price target raised to $76 from $65 at Canaccord
Canaccord analyst Richard Close raised the firm’s price target on Hinge Health (HNGE) to $76 from $65 and keeps a Buy rating on the shares. The firm updated its model…
Hinge Health price target raised to $90 from $75 at KeyBanc
KeyBanc raised the firm’s price target on Hinge Health (HNGE) to $90 from $75 and keeps an Overweight rating on the shares. The firm notes the company held its Investor…
Hinge Health price target raised to $85 from $79 at Truist
Truist raised the firm’s price target on Hinge Health (HNGE) to $85 from $79 and keeps a Buy rating on the shares after the company’s Analyst Day presentation. The firm…
Hinge Health price target raised to $75 from $65 at RBC Capital
RBC Capital analyst Rishi Jaluria raised the firm’s price target on Hinge Health (HNGE) to $75 from $65 and keeps an Outperform rating on the shares after the Hinge Health…
Hinge Health price target raised to $76 from $63 at Needham
Needham analyst Ryan MacDonald raised the firm’s price target on Hinge Health (HNGE) to $76 from $63 and keeps a Buy rating on the shares. The company kicked off the…
Hinge Health price target raised to $70 from $62 at Barclays
Barclays raised the firm’s price target on Hinge Health (HNGE) to $70 from $62 and keeps an Overweight rating on the shares. The company’s investor day focused on new product…
Hinge Health Transcript: Investor Day 2026
The company is scaling a unified digital and in-person care platform for MSK and adjacent conditions, leveraging AI and proprietary data to drive engagement, efficiency, and outcomes. Financial guidance was raised, with new products like migraine and HingeSelect expected to fuel significant incremental growth and margin expansion over the next several years.
Hinge Health Press release: FY 2026
Hinge Health issued a press release on June 10, 2026, disclosing material business information to investors.
Hinge Health Slides: FY 2026
Hinge Health has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Hinge Health adds orthopedic surgery to HingeSelect
Hinge Health (HNGE) announced the expansion of HingeSelect to include orthopedic surgery, now delivering care across the entire musculoskeletal journey. Members begin with first-line treatment and ort...
Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced the expansion of HingeSelect to include orthopedic surgery, now delivering care across the entire musculoskeletal (MSK) ...
Hinge Health raises FY26 revenue view to $818M-$824M, consensus $801.58M
Hinge Health (HNGE) has raised its guidance for the second quarter 2026 and full year 2026, stating that for FY26 it now expects revenue to be between $818M-$824M, reflecting year-over-year…
Hinge Health raises Q2 revenue view to $200M-$202M, consensus $194.95M
Hinge Health (HNGE) has raised its guidance for the second quarter 2026 and full year 2026, stating that for Q2 it now expects revenue to be between $200M-$202M, reflecting year-over-year…
Hinge Health price target raised to $79 from $67 at Stifel
Stifel raised the firm’s price target on Hinge Health (HNGE) to $79 from $67 and keeps a Buy rating on the shares. The company’s positive Q2 pre-announcement reflects scalability and…
Hinge Health hosts its first Investor Day and raises guidance
SAN FRANCISCO--(BUSINESS WIRE)--Tomorrow, June 10, Hinge Health, Inc. (NYSE: HNGE) will host its inaugural Investor Day at Movement - the company's annual conference that brings employers, health plan...
Hinge Health price target raised to $65 from $63 at Canaccord
Canaccord raised the firm’s price target on Hinge Health (HNGE) to $65 from $63 and keeps a Buy rating on the shares. The firm believes that there is upside to…
Hinge Health Transcript: AGM 2026
The meeting confirmed a quorum, elected two Class I directors, and ratified Deloitte as auditor. No shareholder questions were received, and all proposals passed as recommended by the board.
Hinge Health announces results of claims analysis of digital MSK solution
Hinge Health (HNGE) announced the results of the most comprehensive medical claims analysis of its digital musculoskeletal solution, demonstrating an average cost savings of $2,941 per member per year...
Hinge Health proven to deliver 3.0x ROI with the largest study of its kind
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced the results of the most comprehensive medical claims analysis of its digital musculoskeletal (MSK) solution, demonstrati...
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...